Iovance Biotherapeutics (IOVA) Assets (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported Assets for 17 consecutive years, with $925.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Assets fell 4.25% year-over-year to $925.7 million; the TTM figure through Mar 2026 stood at $925.7 million (down 4.25% YoY), while the FY2025 annual figure was $913.2 million, changed 0.3% from the prior year.
• Assets rose to $925.7 million in Q1 2026 per IOVA's latest filing, from $913.2 million in the prior quarter.
• Across five years, Assets topped out at $966.7 million in Q1 2025 and bottomed at $545.9 million in Q3 2022.
• Historically, Assets has averaged $809.0 million across 5 years, with a median of $852.3 million in 2023.
• Annual changes were most pronounced in 2022 — Assets slumped 34.13% — and 2023, when it soared 56.12%.
• Iovance Biotherapeutics' Assets stood at $664.0 million in 2022, then grew by 17.53% to $780.4 million in 2023, then advanced by 16.67% to $910.4 million in 2024, then grew by 0.3% to $913.2 million in 2025, then increased by 1.37% to $925.7 million in 2026.
• Business Quant data shows IOVA's Assets at $925.7 million in Q1 2026, $913.2 million in Q4 2025, and $904.9 million in Q3 2025.